Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ACP1 | P24666 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753025 | 0.87 | ACHE (0.64) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1753120 | 0.87 | CYP3A4 (0.64) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752931 | 0.82 | ACHE (0.72) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752875 | 0.82 | ACHE (0.72) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1752978 | 0.80 | LMNA (0.80) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| Minaprine SCHEMBL49371 | 0.78 | ACHE (1.00) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL14069119 | 0.78 | ACHE (0.75) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL1753092 | 0.78 | ACHE (0.75) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| Minaprine SCHEMBL124092 | 0.77 | CYP3A4 (1.00) | ACHELMNACYP3A4CYP1A2CYP2D6 | |
| Minaprine SCHEMBL124094 | 0.77 | CYP3A4 (1.00) | ACHELMNACYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2592075-B1 | PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-1812408-B1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIV NORTHWESTERN (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2592075-A1 | Pyridazine compounds for the treatment of inflammatory diseases | Northwestern University (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| WO-2008109437-A2 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007130383-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007127475-A2 | PYRIDAZINES FOR DEMYELINATING DISEASES AND NEUROPATHIC PAIN | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127474-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | ACHE 178/4885LMNA 2191/4885CYP3A4 963/4885 |
| US-20090197885-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | ACHE 1/4885LMNA 2503/4885CYP3A4 1770/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | ACHE 214/4885LMNA 2393/4885CYP3A4 1218/4885 |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | ACHE 172/4885LMNA 2192/4885CYP3A4 979/4885 |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | C5, PNPO, CHRNA5 | ACHE 225/4885LMNA 1094/4885CYP3A4 344/4885 |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | ACHE 178/4885LMNA 2191/4885CYP3A4 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.